secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0000950170-25-034689
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences reports FY2024 net loss of $15.0M; cash at $6.5M, expects to fund ops into 2025
--------------------------------------------------------------------------------

- Q4 2024 net loss $1.7M ($4.98/share) vs $2.2M ($133.64/share) in Q4 2023.
- FY2024 net loss $15.0M ($87.68/share) vs $0.1M ($8.44/share) in FY2023.
- Cash and equivalents $6.5M at Dec 31, 2024, down from $12.0M a year ago.
- Operating cash burn $18.3M in FY2024 vs $7.3M in FY2023.
- Phase 1b PRIME study of Gemini in CKD patients dosing; topline data expected mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017025034689/0000950170-25-034689-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017025034689/revb-20250306.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-034689

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer